Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Open-label Study of Betalutin in Combination With Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma (Archer-1)

Trial Profile

A Phase 1b Open-label Study of Betalutin in Combination With Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma (Archer-1)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lutetium-(177lu) lilotomab satetraxetan (Primary) ; Lutetium-(177lu) lilotomab satetraxetan (Primary) ; Rituximab (Primary)
  • Indications Follicular lymphoma
  • Focus Adverse reactions
  • Acronyms ARCHER-1
  • Sponsors Nordic Nanovector
  • Most Recent Events

    • 17 Sep 2019 Results presented in the Nordic Nanovector media release.
    • 17 Sep 2019 According to a Nordic Nanovector media release, Dr Arne Kolstad will present data from the first safety cohort of three patients of this trial.
    • 21 May 2019 According to a Nordic Nanovector media release,data read-out is expected during the second half of 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top